To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai
TorreyPines Therapeutics, Inc. has announced that it has agreed to sell its Alzheimer's disease genetics research program to Eisai Co., Ltd. for an upfront cash payment.
TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer's disease genetics research program focused on the discovery of Alzheimer's disease targets using whole-genome family-based association screening.
"We are pleased to announce the sale of our genetics program to our long-time partner, Eisai," said Ev Graham, acting chief executive officer of TorreyPines Therapeutics. "The sale of this asset furthers our transition to a development-only company and enables us to focus our resources on advancing our clinical stage assets: tezampanel, NGX426 and NGX267. As a leader in treating Alzheimer's disease we believe Eisai is well positioned to capitalize on the discoveries from the genetics program."
The genetics program is one of two TorreyPines discovery programs focused on Alzheimer's disease, the other being a gamma secretase modulator (GSM) program.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
